Batavia Bioservices and UvA Holding Announce STEP™ Technology Exclusive License
News Apr 29, 2013
Under the agreement, Batavia Bioservices has been granted the exclusive license to the STEP™ technology, a revolutionary, plasmid-based system that significantly reduces the time required to develop recombinant protein-producing mammalian cell lines while increasing protein production more than 10-fold.
Menzo Havenga (CEO Batavia Bioservices) commented: “We are very pleased that UvA Holding has selected Batavia Bioservices as its marketing partner for STEP™ technology since we firmly believe that this technology will significantly reduce manufacturing costs."
Chris Yallop (COO Batavia Bioservices) added: “STEP™ technology also allows the development of so-called rare diseases biopharmaceutical products, which have always been considered too expensive to develop."
Piet Scholten (Director UvA Holding BV) concluded: “With their in-depth know how in biopharm manufacturing, vast network, and presence in both Europe and USA, Batavia Bioservices provided the ideal landing platform for marketing our technology and we look forward to a fruitful relationship!”
Financial details of the exclusive license agreement were not disclosed.
How Ribosomes Shape the ProteomeNews
Cells are crowded with macromolecules, which limits the diffusion of proteins, especially in prokaryotic cells without active transport in the cytoplasm. While investigating the relationship between crowding, ionic strength and protein diffusion, biochemists made a fascinating discovery: positively charged proteins stick to the surface of ribosome complexes. This explains why most water-soluble proteins carry an overall negative charge.READ MORE
Public Resource of Cellular Effects of Drugs and Genes Boosts Drug Discovery and Offers Insights Into Protein FunctionNews
Researchers have taken the Connectivity Map — a widely used resource of tools and data — to new heights with a massively scaled-up version including more cell types, more perturbations, and more types of data, including proteomic and cellular imaging data. For this new platform, the researchers have also improved its accessibility for the scientific community, enabling studies of small molecule and gene function and informing clinical trials.READ MORE